No Data
BJ HEALTH: ANNOUNCEMENT OF THE ANNUAL RESULTS FOR THE YEAR ENDED 31 DECEMBER 2024
BJ HEALTH (02389.HK) expects an increase in annual losses.
Gelonghui on March 14丨BJ HEALTH (02389.HK) announced that the company expects the loss attributable to owners for the fiscal year ending December 31, 2024, to increase by approximately 55,000,000 HKD compared to the same period in 2023. In this fiscal year, the group's daily Operation Business remained relatively stable, and the increase in loss is mainly due to the impact of the following net increase in expenses: (1) due to the devaluation of the Canadian dollar and the RMB, a foreign exchange loss of approximately 29,290,000 HKD was recorded this year, while a foreign exchange gain of approximately 9,237,000 HKD was recorded in the same period last year; (2) the listed associates held by the group.
Beijing Health to Review 2024 Financial Results and Dividend
BJ HEALTH (02389.HK) held a Board of Directors meeting on March 28 to consider and approve the annual performance.
Gelonghui March 3丨BJ HEALTH (02389.HK) announced that the company will hold a Board of Directors meeting on March 28, 2025 (Friday) to consider and approve the group's annual performance for the year ending December 31, 2024, and to discuss the distribution of the final dividend (if any), as well as to address Other matters.
Luoxin Pharmaceuticals Group Stock (002793.SZ): Plans to increase capital for its controlling subsidiary BJ HEALTH.
On December 24, Gelonghui reported that Luoxin Pharmaceuticals Group Stock (002793.SZ) announced that its controlling subsidiary, Luoxin Health Technology Development (Beijing) Co., Ltd. (referred to as "BJ HEALTH"), currently has a registered capital of 233.6 million yuan, and plans to increase the registered capital by 120 million yuan. The company intends to subscribe to the aforementioned increased registered capital of BJ HEALTH at a price of 120 million yuan using its own funds. Once this capital increase is completed, the registered capital of BJ HEALTH will change to 353.6 million yuan. Regarding this capital increase, the other existing Shareholders of BJ HEALTH include Chengdu Deyi Xinhua Private Equity Investment Partnership.
bj health (02389.HK): Yang Xiaoyan appointed as an independent non-executive director.
Grain live December 2nd, bj health (02389.HK) announced that starting from December 2, 2024, Yang Xiaoyan has been appointed as an independent non-executive director and a member of the audit committee, nomination committee, and remuneration committee respectively.